A Study to Understand About the Study Medicine Palbociclib in Breast Cancer Patients After it is Out in the Japanese Market
- Status
- COMPLETED
- Phase
- N/A
Clinical Trials Related to Fulvestrant
Related studies linked through entity extraction aliases.
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
- Status
- RECRUITING
- Phase
- PHASE3
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KSHN001034 in Healthy Postmenopausal Female Volunteers
- Status
- RECRUITING
- Phase
- PHASE1
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
- Status
- RECRUITING
- Phase
- PHASE2
Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3
A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer
- Status
- RECRUITING
- Phase
- NA
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1
SNV4818 in Participants With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors
- Status
- RECRUITING
- Phase
- PHASE1
Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2